Get the Stockscreener App
83.05
0.06%
0.05
After Hours:
82.68
-0.37
-0.45%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $83.05, with a volume of 5.07M.
It is up +0.06% in the last 24 hours and up +4.79% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$83.00
Open:
$84.02
24h Volume:
5.07M
Relative Volume:
1.28
Market Cap:
$257.50B
Revenue:
$49.13B
Net Income/Loss:
$6.44B
P/E Ratio:
41.94
EPS:
1.98
Net Cash Flow:
$6.97B
1W Performance:
-5.22%
1M Performance:
+4.79%
6M Performance:
+27.24%
1Y Performance:
+23.96%
1-Day Range:
$82.93
$84.30
1-Week Range:
$82.46
$87.25
52-Week Range:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Morton Community Bank Boosts Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca Unit Owes $130M In Chancery Scuttled-Drug Suit - Law360
AstraZeneca rises Friday, outperforms market - MarketWatch
As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider? - Yahoo Finance UK
3 Market-Beating Stocks to Buy for Less Than $100 - The Motley Fool
China detains AstraZeneca staff in data, drug-import probes - The Spokesman Review
Trending tickers: NatWest, AstraZeneca, Shopify, Coinbase - Yahoo Finance UK
AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities - AOL
AstraZeneca’s Alexion Hit With Damages Exceeding $130 Million - Bloomberg Law
AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities - Yahoo Finance
FDx Advisors Inc. Sells 6,044 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca Believes Size Matters In Amyloidosis - Scrip
AstraZeneca falls Thursday, underperforms market - MarketWatch
China detains AstraZeneca staff in data, drug-import probes: Report - The New Indian Express
AstraZeneca, a mega-cap growth stock that just got cheaper! - Yahoo Finance UK
AstraZeneca slides after confirming five employees held by China police - Proactive Investors USA
Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report - GlobeNewswire Inc.
AstraZeneca slides after confirming five employees held by China police - Proactive Investors Australia
Subscribe to read - Financial Times
China detains AstraZeneca employees in illegal activities probe - Al Arabiya English
China Detains AstraZeneca Staff in Data, Drug-Import Probes - Yahoo Finance
China detains AstraZeneca staff in data, drug-import probes, Bloomberg News reports - Marketscreener.com
China Detains AstraZeneca Staff in Data, Drug-Import Probes - BNN Bloomberg
Trending tickers: AMD, Shell, AstraZeneca, HubSpot - Yahoo Finance UK
AstraZeneca, Samsung Biologics Settle Soliris Biosimilar Lawsuit - Bloomberg Law
AstraZeneca Looks To Clinical Trial Innovations To Help Meet Oncology Ambitions - Scrip
Europe Breast Cancer Screening Market Forecast Report and Company Analysis 2024-2032 Featuring AstraZeneca, Novartis, Sanofi, Pfizer, Bayer, and GlaxoSmithKline - Yahoo Finance
AstraZeneca in first COVID-19 vaccine deal with Chinese company - Yahoo News UK
Cozad Asset Management Inc. Buys 8,400 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Is AstraZeneca PLC (AZN) the Best Cancer Stock to Buy Now? - Yahoo Finance
Several Reasons for the Outperformance of Astrazeneca Plc (AZN) - MSN
AstraZeneca PLC ADR falls Tuesday, still outperforms market - MarketWatch
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs - Benzinga
AstraZeneca falls Tuesday, still outperforms market - MarketWatch
Naviter Wealth LLC Increases Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca reports total voting rights as of August end - Investing.com
AstraZeneca: to present its advances in oncology - Marketscreener.com
Trending tickers: latest investor updates on Gold, Ryanair, Nvidia and AstraZeneca - Yahoo Finance UK
Several Reasons for the Outperformance of Astrazeneca Plc (AZN) - Yahoo Finance
AstraZeneca PLC (AZN): A Good 52-Week High Stock to Buy According to Short Sellers - MSN
AstraZeneca PLC (AZN): A Good 52-Week High Stock to Buy According to Short Sellers - Yahoo Finance
Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030 - GlobeNewswire Inc.
AstraZeneca rises Monday, outperforms market - MarketWatch
AstraZeneca Shares and Voting Rights Update - TipRanks
Here’s why H1 results could boost the AstraZeneca share price - Yahoo Finance UK
AstraZeneca (LON:AZN) Reaches New 12-Month High at $13,372.00 - MarketBeat
FY2025 EPS Estimates for AstraZeneca PLC (NASDAQ:AZN) Boosted by Analyst - MarketBeat
AstraZeneca hits £200bn as its share price soars. Can I afford to miss out? - Yahoo Finance UK
Barlow Wealth Partners Inc. Boosts Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider? - MSN
As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider? - Motley Fool UK
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):